← Product Code [HSB](/productcode/HSB) · K260146 # FITBONE® TRANSPORT AND LENGTHENING SYSTEM (K260146) _Orthofix Srl · HSB · May 19, 2026 · Orthopedic · SESE_ **Canonical URL:** https://fda.innolitics.com/device/K260146 ## Device Facts - **Applicant:** Orthofix Srl - **Product Code:** [HSB](/productcode/HSB.md) - **Decision Date:** May 19, 2026 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 888.3020 - **Device Class:** Class 2 - **Review Panel:** Orthopedic - **Attributes:** Therapeutic ## Indications for Use Fitbone Transport and Lengthening System is indicated for limb lengthening, open and closed fracture fixation, pseudoarthrosis, malunions, non-unions, or bone transport of the long bones. The Fitbone Transport and Lengthening System is indicated for adult only. ## Device Story Implantable intramedullary pulling transport nail; implanted in femur or tibia medullary canal; connected to subcutaneous receiver via bipolar feed line. External control set (electronics station/transmitter) induces electromagnetic field; receiver converts to DC voltage to power internal motor; motor drives telescope distraction. Used in operating theatre by surgeons; distraction activated by patient at home or in clinic. Retraction mode restricted to HCPs for over-distraction or plan adjustments. Provides controlled bone lengthening/transport; benefits patients with limb length discrepancies or bone defects. ## Clinical Evidence Bench testing only. Performance verified via mechanical testing including inverted load test, static 4-point bending, fatigue 4-point bending, and torsional testing per ASTM F1264-16. ## Technological Characteristics Intramedullary fixation rod; stainless steel 1.4441 (ASTM F138) and medical grade silicone. Distraction via internal motor powered by electromagnetic induction from external transmitter to subcutaneous receiver. Lengths 290-490mm; diameters 11-13mm. Sterilization: H2O2 plasma. Standalone implant system with external control unit. ## Regulatory Identification An intramedullary fixation rod is a device intended to be implanted that consists of a rod made of alloys such as cobalt-chromium-molybdenum and stainless steel. It is inserted into the medullary (bone marrow) canal of long bones for the fixation of fractures. ## Predicate Devices - FITBONE® Transport and Lengthening System ([K232169](/device/K232169.md)) ## Reference Devices - FITBONE® TAA ([K163368](/device/K163368.md)) - FITBONE® TAA ([K203399](/device/K203399.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} FDA U.S. FOOD & DRUG ADMINISTRATION May 19, 2026 Orthofix Srl Chiara Zuliani Senior Technical Product RA Specialist Via Delle Nazioni, 9 Bussolengo (Vr), IT 37012 Italy Re: K260146 Trade/Device Name: Fitbone® Transport And Lengthening System Regulation Number: 21 CFR 888.3020 Regulation Name: Intramedullary fixation rod Regulatory Class: Class II Product Code: HSB Dated: April 16, 2026 Received: April 17, 2026 Dear Chiara Zuliani: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov {1} K260146 - Chiara Zuliani Page 2 Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory- {2} K260146 - Chiara Zuliani Page 3 assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, FARZANA SHARMIN -S Farzana Sharmin, PhD Assistant Director DHT6A: Division of Joint Arthroplasty Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {3} | Indications for Use | | | | --- | --- | --- | | Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. | K260146 | ? | | Please provide the device trade name(s). | | ? | | FITBONE® TRANSPORT AND LENGTHENING SYSTEM | | | | Please provide your Indications for Use below. | | ? | | Fitbone Transport and Lengthening System is indicated for limb lengthening, open and closed fracture fixation, pseudoarthrosis, malunions, non-unions, or bone transport of the long bones. The Fitbone Transport and Lengthening System is indicated for adult only. | | | | Please select the types of uses (select one or both, as applicable). | ☑ Prescription Use (21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | ? | {4} ORTHOFIX K260146-Page 1 # 510(K) SUMMARY # ORTHOFIX SRL # FITBONE® Transport and Lengthening System ## Submitter information | Company Name: | Orthofix S.r.l. | | --- | --- | | Address | Via Delle Nazioni, 9 37012 Bussolengo (VR) - Italy | | Telephone | +39 045 6719000 | | Fax | +39 045 6719380 | | Contact Person | Chiara Zuliani Senior Technical Product RA Specialist | | --- | --- | | Address | Via Delle Nazioni, 9 37012 Bussolengo (VR) - Italy | | Telephone | +39 045 6719000 | | Fax | +39 045 6719380 | | Email address | chiarazuliani@orthofix.it | | Date of submission | 2026, January 19 | ## Trade Name, Common Name, Classification Trade Name: FITBONE® Transport and Lengthening System Common Name: Rod, Fixation, Intramedullary and Accessories Classification Name: Intramedullary Fixation rod Regulation Number: 21 CFR 888.3020 Product Code: HSB Classification: Class II Panel code: Orthopedic ## Predicate devices and additional reference device | Primary Predicate | 510(k) Number | Manufacturer | | --- | --- | --- | | FITBONE® Transport and Lengthening System | K232169 | Orthofix s.r.l. | | Reference Device | 510(k) Number | Manufacturer | | FITBONE® TAA | K163368 | Orthofix s.r.l. | | | K203399 | | ## Device description The subject Fitbone® transport and lengthening system consists of the implantable intramedullary pulling transport nails and is a line extension of the existing primary predicate Fitbone® transport and lengthening nails (K232169). The Subject device is implanted into the medullary canal of the femur or tibia and connected to the additional predicate/reference device intracutaneous Receiver (K203399 and K163368) by a bipolar feed line. The external FITBONE Control Set is identical to that previously Via delle Nazioni 9 | 37012 Bussolengo | Verona, Italy +39.045.6719000 orthofix.com ORTHOFIX SRL ORTHOFIX TECNOPIANISTICI Orthofix Medical Inc. Cintamano SEDE LEGALE: VALVITTORI PISANI 90 | 20014 MILANO UTAIJA | C.F. e PISA DIRITENZI 100 | CZE: VIST NUMBER (TOPI/1N08750) Registro Imprese di Milano DIR70040/50 | R.E.A. M11257/89 | Cap. Soc. Eur. 1546.000 mt. vers. SEDE SECONDARIA: VALDELLE NAZIONI, 9 | 37012 BUSSOLENGO, MERONALI ITALIA | Registro Imprese di Verona | R.E.A. VR 215209 {5} ORTHOFIX® K260146-Page 2 | | cleared for the additional predicate/reference device Fitbone TAA device (K203399, K163368) and consists of a control electronics station and transmitter. The power required for the distraction process is controlled by hermetically enclosed motor which draws the telescope apart. The electro-magnetic field sent from the Transmitter to the Receiver is converted in the Receiver into DC-Voltage to supply the motor of the subject Fitbone® transport and lengthening nails with voltage, when actioned. The nail is anchored to the bone by locking screws through medial-lateral and AP holes in the nail depending on the configuration holes in the nail. The energy needed for the distraction process is transmitted from the outside by placing the external transmitter over the implanted receiver, which is placed in the subcutaneous tissue during surgery. There is no transcutaneous contact between the implanted intramedullary nail and the outer surface of the patient's body. The subject nails, as the primary predicate Fitbone® transport and lengthening system, in same sterile conditions are made from implant grade stainless steel 1.4441, according to ASTM F138 “Standard Specification for Wrought 18Chromium-14Nickel-2.5Molybdenum Stainless Steel Bar and Wire for Surgical Implants (UNS S31673)”, and medical grade Silicone. The Subject, as the predicates, will be implanted only by Healthcare Professionals (HCP), with full awareness of the appropriate orthopedic procedures (including application and removal), in the operating theatre only. The limb distraction of the femur and tibia treatment will be activated in home by the patient or clinic theatres. The retraction mode of the intramedullary nail will be operated only by HCPs, in case of unintended over-distraction or if nail Rewind & Go is needed as per preoperative plan. | | --- | --- | | Indications for use | Fitbone Transport and Lengthening System is indicated for limb lengthening, open and closed fracture fixation, pseudoarthrosis, malunions, non-unions, or bone transport of the long bones. The Fitbone Transport and Lengthening System is indicated for adult only. | | Technological Characteristics | The following table provides a comparison and assessment of fundamental scientific principles and technological characteristic of the subject, primary and additional reference device. Any differences have been demonstrated not to raise different issues of safety or performance by virtue of objective evidence (e.g., bench testing, process validations, etc.). Therefore, *technological characteristics* of the new Subject Fitbone® transport and lengthening nails are substantially equivalent to the primary predicate Fitbone® transport and lengthening system (K232169) and reference device. | | Technological Characteristic | | Subject Device (Fitbone® transport and lengthening system) | Predicate Device Fitbone® transport and lengthening system, K232169) | Additional Reference Device (Fitbone TAA, K163368 and K203399) | | --- | --- | --- | --- | --- | | 1 | Nail Material | Stainless steel (1441-AISI 316LVM) | Stainless steel (1441-AISI 316LVM) | Stainless steel (1441-AISI 316LVM) | | | | Assessment: The material is the same as the primary and reference predicates. Equivalent - no different questions of safety and effectiveness raised. | | | | 2 | | H_{2}O_{2} Plasma | H_{2}O_{2} Plasma | H_{2}O_{2} Plasma | Via delle Nazioni 9 | 37012 Bussolengo | Verona, Italy +39.045.6719000 orthofix.com ORTHOFIX® COORDINATING OTHER MEDICAL PROCEDURE SEDE LEGALE: VIA VITTORI PISANI 9 | 37014 MILANO UTAVIA F.C.F. e P.IVA DI INTERIORO (CIT): VIA NUMERO TERRINO 0116 | Registro Imprese di Milano 0017000010 | RELA: M15757169 | Cap. Soc. Eur. 1546.000 mt. vers. SEDE SECONDARIA: VIA DELLE NAZIONI 9 | 37012 BLISSOLENGO DIERONALI ITALIA | Registro Imprese di Verona RELA: VR 215209 {6} ORTHOFIX® K260146-Page 3 | | Sterilization Method | Assessment: the subject’s device sterilization method (H₂O₂ plasma) is equivalent to the primary predicate and to additional predicate/reference device. Equivalent - no different questions of safety and effectiveness raised | | | | --- | --- | --- | --- | --- | | 3 | Nail Size Range | 290-490mm in length; 11 and 13mm diameters in varying configurations | 290-490mm in length; 11 and 13mm diameters in varying configurations | Not applicable | | | | Assessment: Size ranges of subject devices are equivalent to the primary. Equivalent - no different questions of safety and effectiveness raised | | | | 4 | Maximum Bone Transport Stroke Available | 80 mm | 80 mm | Not applicable | | | | Assessment: The transport stroke length of the subject device is the same of the primary predicate. Equivalent - no different questions of safety and effectiveness raised | | | | 5 | Method of Distraction/Energy Source | Internal motor electro-magnetically induced by an external transmitter with signal received through a receiver placed just under skin | Internal motor electro-magnetically induced by an external transmitter with signal received through a receiver placed just under skin | Internal motor electro-magnetically induced by an external transmitter with signal received through a receiver placed just under skin | | | | Assessment: Subject distraction methodology is equivalent to the primary and reference devices. Equivalent - no different questions of safety and effectiveness raised | | | | Performance Analysis | | Mechanical testing/rationale of the subject devices to demonstrate equivalence in function and safety for the intended use of the subject Fitbone Transport Pulling nails in respect to the existing primary predicate Fitbone® transport and lengthening nails (K232169) have been performed for the following functional attributes: • Implantable rod: Inverted Load test for pulling nails with subject Fitbone Transport Pulling nails, • Implantable rod: Static 4-point bending test performed according to ASTM F1264-16 - Standard Specification and Test Methods for Intramedullary Fixation Devices on the primary predicate Fitbone® transport and lengthening nails (K232169) is deemed applicable to the subject devices, • Implantable rod: Fatigue 4-point bending test performed according to ASTM F1264-16 - Standard Specification and Test Methods for Intramedullary Fixation Devices on the primary predicate Fitbone® transport and lengthening nails (K232169) is deemed applicable to the subject devices, • Implantable rod: Torsional test performed according to ASTM F1264-16 - Standard Specification and Test Methods for Intramedullary Fixation Devices on the primary predicate Fitbone® transport and lengthening nails (K232169) is deemed applicable to the subject devices, | | | Via delle Nazioni 9 | 37012 Bussolengo | Verona, Italy +39.045.6719000 orthofix.com ORTHOFIX® COORDINAMENTO Orthofix Medical Inc. Caltamano SEDE LEGALE: VIA VITTORI PISANI 9 | 37014 MILANO ITALIA | C.F. e PISA DIRITENZI 10 | CZE: VAT NUMER ITO2011600700 | Registro Imprese di Milano 0017000350 | R.E.A. MI 5717169 | Cap. Soc. Eur. 1546.000 int. vero SEDE SECONDARIA: VIA DELLE NAZIONI 9 | 37051 BUGGELENGO, MERENIGI ITALIA | Registro Imprese di Verona | R.E.A. VR 215209 {7} ORTHOFIX® K260146-Page 4 | Conclusion | Based upon equivalences in: intended use, patient population, site of application, conditions of use, operating principles, and the non-clinical performance data, the new nail model of FITBONE® Transport and Lengthening System have been shown to be safe and effective and to perform equivalently as compared to the legally marketed predicate device. Therefore, the subject new nail model of FITBONE® Transport and Lengthening System is substantially equivalent to the legally marketed predicate devices and the reference device chosen as basis for the scientific methodology. | | --- | --- | Via delle Nazioni 9 | 37012 Bussolengo | Verona, Italy +39.045.6719000 orthofix.com ORTHOFIX® COORDINAMENTO Orthofix Medical Inc. Elefawano SEDE LEGALE: VIA VITTORI PISANI 90 | 22124 MILANO UTAIJA | C.F. A PISA 28970080100 LOTE: VAT NUMBER (TOININV00756) Registro Imprese di Milano 00970080100 | R.E.A. MI 5257769 / Cap. Soc. Eur. 15465000 mt. verb SEDE SECONDARIA: VIA DELLE NAZIONI 9 | 37012 BUSSOLENGO, VERONA | ITALIA | Registro Imprese di Verona | R.E.A. VR 215209 --- **Source:** [https://fda.innolitics.com/device/K260146](https://fda.innolitics.com/device/K260146) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com